Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

  1. Moreau, P.
  2. Stewart, K.A.
  3. Dimopoulos, M.
  4. Siegel, D.
  5. Facon, T.
  6. Berenson, J.
  7. Raje, N.
  8. Berdeja, J.G.
  9. Orlowski, R.Z.
  10. Yang, H.
  11. Ma, H.
  12. Klippel, Z.
  13. Zahlten-Kumeli, A.
  14. Mezzi, K.
  15. Iskander, K.
  16. Mateos, M.-V.
Aldizkaria:
Cancer Medicine

ISSN: 2045-7634

Argitalpen urtea: 2020

Alea: 9

Zenbakia: 9

Orrialdeak: 2989-2996

Mota: Artikulua

DOI: 10.1002/CAM4.2945 GOOGLE SCHOLAR lock_openSarbide irekia editor